ClinicalTrials.Veeva

Menu

The Effectiveness of Ankaferd Blood Stopper in the Management of Traumatic Bleeding

H

Haydarpasa Numune Training and Research Hospital

Status

Completed

Conditions

Bleeding Disorder

Treatments

Procedure: Ankaferd Blood Stopper in theTraumatic Bleeding

Study type

Interventional

Funder types

Other

Identifiers

NCT03871452
h8w67r3k

Details and patient eligibility

About

The objective of this study was to prospectively compare effectiveness of Ankaferd Blood Stopper (ABS) with dry sponges in cessation of bleeding in adult trauma cases with external bleeding due to extremity lacerations.

Methods: The study was conducted on patients with bleeding associated with extremity lacerations. All consecutive patients presented to the emergency department of the high-volume training hospital in Istanbul were recruited within the study period

Full description

This study was planned as a prospective randomized study. After local ethics committee approval, all consecutive patients admitted to the Emergency Department of the Haydarpasa Numune Training & Research Hospital due to extremity lacerations between October 1st and October 11th 2018 were recruited. The longest duration for wound healing, infection follow-up, and suture removal was 12 days. Therefore, the study was completed in a total of 23 days after suture removal of the last case.

ABS which was approved in 2017 by the Ministry of Health, is being used routinely in the management of the patients with traumatic bleeding in the emergency department of the hospital. Nurses working in treatment areas of the department were trained for this prospective study. They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.

The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses (group II). Demographic data, systemic disease history, drugs used, injury mechanism, habits etc. of the patients enrolled in the study were recorded into data collection form.

Forty commercially prepared ABS-soaked wet sterile sponges and 40 dry sponges of 2.5x7 cm were randomly numbered and placed in a box in the study area. Random numbers table was used to generate the sequence of enumeration of the sponges. Any given patient was treated with the next sponge with the smallest number in the box and data sheets contained the number of the sponge with which the patient's bleeding was intervened. Therefore, allocation concealment was accomplished for the study purposes.

In both groups, lacerations that did not stop bleeding within 10 minutes and lacerations with recurred bleeding within the half-hour follow-up period were repaired by the primary suturing. Lacerations were sutured at the end of follow-up period in other patients. Daily dressing was recommended to the patients at discharge, and they were invited for a follow-up visit 3 days later. They were followed-up for wound infection. Suture removal date was recorded in data collection form.

Statistical analysis was conducted by using the MedCalc Statistical Software version 12.7.7 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2013). Descriptive statistics were used to define continuous variables in this study (mean, standard deviation, range, and median). Mann Whitney U test was used to compare two independent and abnormally distributed groups. Chi-square test was performed to compare categorical variables, or Fisher's Exact test was performed where appropriate or required. Statistical significance level was determined as p<0.05.

Enrollment

80 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Adult patients (18 years-old and above)
  • presented with isolated cuts on the extremities
  • cuts sized between 1 and 5 centimeters .

Exclusion criteria

  • Patients under 18 years of age
  • with only superficial abrasions
  • with lacerations smaller than 1 cm and larger than 5 cm
  • irregular laceration borders or star-like lacerations
  • deep lacerations requiring subcutaneous suturing
  • lacerations requiring additional interventions such as tendon repair controlled bleeding
  • grade III and IV systemic diseases (advanced heart failure, uncontrolled hypertension, etc.) according to American Society of Anesthesiologists (ASA) classification,
  • who received radiotherapy or chemotherapy for malignancies within the last three months
  • with the history of hematologic diseases such as leukemia
  • using medications leading to hemorrhage risk (oral anticoagulants, aspirin, etc.)
  • congenital coagulation factor deficiency such as hemophilia
  • multiple trauma and abnormal vital signs

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

80 participants in 2 patient groups

ABS in external bleeding
Active Comparator group
Description:
Drug Ankaferd Blood Stopper Bleeding control in 10 minutes with ABS
Treatment:
Procedure: Ankaferd Blood Stopper in theTraumatic Bleeding
Repetition of ABS stopped bleeding
Active Comparator group
Description:
Repetition of ABS stopped bleeding
Treatment:
Procedure: Ankaferd Blood Stopper in theTraumatic Bleeding

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems